DOCSLIB.ORG

Bk Sans 005737.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bk Sans 005737.Pdf TABLE OF CONTENTS Procter & Gamble’s Earnings Per Share .3 Coca-Cola’s Earnings Per Share .3 Johnson & Johnson’s Earnings Per Share .4 United Continental’s Earnings Per Share .4 Ford Motor Company’s Earnings Per Share .5 Advance Micro Devices, Inc.’s Earnings Per Share .5 Compare Coca-Cola to Ford Motor Company .6 American Express Company .7 American Express Company Per Share Earnings History .8 The Bank of New York Mellon (BNY Mellon) .9 BNY Mellon EPS History / BNY Mellon BVPS History .10 Coca-Cola Company .11 ConocoPhillips .12 ConocoPhillips EPS History / ConocoPhillips BVPS History .13 Costco Wholesale Corporation .14 Costco EPS History / Costco BVPS History .15 GlaxoSmithKline .16 GSK’s brand-name products .17 GlaxoSmithKline’ Profile / GlaxoSmithKline’ History .18 Johnson & Johnson .19 Johnson & Johnson Per Share Book Value History .20 Kraft Foods, Inc .21 Kraft Foods EPS History / Kraft Foods BVPS History .22 Moody’s Corporation .23 Moody’s Corporation EPS History .24 Procter & Gamble Company .25 Procter & Gamble BVPS History .26 Sanofi S. A. .27 Sanofi A.S EPS ADR History / Sanofi A.S BVPS History .28 Torchmark Corporatio .29 Torchmark Corporation EPS History / Torchmark Corporation BVPS History .30 Union Pacific Corporation .31 Union Pacific Corporation NPM (Net Profit Margin) History .32 Union Pacific Corporation BVPS History / Union Pacific Corporation EPS History .32 U.S. Bancorp .33 U.S. Bankcorp EPS History / U.S. Bankcorp BVPS History .34 Wal-Mart Stores, Inc. .35 Walmart EPS History / Walmart BVPS History .36 Washington Post Company .37 Washington Post Company EPS History / Washington Post Company BPVS History .38 Wells Fargo & Company .39 Wells Fargo & Company EPS History / Wells Fargo & Company BVPS History .40 BYD .41 Procter & Gamble’s Earnings Per Share YEAR EPS (Earnings Per Share, $) ’11 3.98 ’10 3.53 ’09 3.58 ’08 3.64 ’07 3.04 ’06 2.76 ’05 2.53 ’04 2.32 ’03 2.04 ’02 1.80 ’01 1.56 Coca-Cola’s Earnings Per Share YEAR EPS (Earnings Per Share, $) ’11 3.85 ’10 3.49 ’09 2.93 ’08 3.02 ’07 2.57 ’06 2.37 ’05 2.17 ’04 2.06 ’03 1.95 ’02 1.65 ’01 1.60 3. Johnson & Johnson’s Earnings Per Share `YEAR EPS (Earnings Per Share, $) ’11 4.85 ’10 4.76 ’09 4.63 ’08 4.57 ’07 4.15 ’06 3.76 ’05 3.50 ’04 3.10 ’03 2.70 ’02 2.23 ’01 1.91 United Continental’s Earnings Per Share YEAR EPS (Earnings Per Share, $) ’11 4.75 ’10 4.30 ’09 -7.49 ’08 -13.63 ’07 2.32 ’06 -0.16 ’05 -4.88 ’04 -9.87 ’03 -15.20 ’02 -34.56 ’01 -33.23 4. Ford Motor Company’s Earnings Per Share YEAR EPS (Earnings Per Share, $) ’11 2.00 ’10 1.66 ’09 0.86 ’08 -6.50 ’07 -1.43 ’06 -6.72 ’05 0.86 ’04 1.59 ’03 0.35 ’02 0.19 ’01 -2.95 Advance Micro Devices, Inc.’s Earnings Per Share YEAR EPS (Earnings Per Share, $) ’11 0.55 ’10 0.64 ’09 0.45 ’08 -4.03 ’07 -5.09 ’06 -0.28 ’05 0.37 ’04 0.25 ’03 -0.79 ’02 -3.81 ’01 -0.18 5. Compare Coca-Cola to Ford Motor Company Coca-Cola YEAR BVPS (Book Value Per Share, $) ’11 14.60 ’10 13.43 ’09 10.77 ’08 8.85 ’07 9.38 ’06 7.30 ’05 6.90 ’04 6.61 ’03 5.77 ’02 4.78 ’01 4.57 ’00 3.75 ’99 3.85 ’98 3.41 ’97 2.96 ’96 2.48 ’95 2.15 Ford Motor YEAR BVPS (Book Value Per Share, $) ’11 2.90 ’10 0.40 ’09 -2.43 ’08 - 7.22 ’07 2.55 ’06 -1.83 ’05 7.02 ’04 8.76 ’03 6.36 ’02 3.07 ’01 4.28 ’00 9.75 ’99 22.53 ’98 20.36 ’97 24.83 ’96 21.91 ’95 21.45 6. American Express Company: Key Statistics Address: 200 Vesey Street New York, NY 10285 USA Telephone: (212) 640-2000 Website: www.americanexpress.com Industry: Global Payments, Charge and Credit Cards, Travel Service Key Statistics: Public Company Founded in 1850 Employees: 58,300 Revenue: $30.2 billion (2011) Net Earnings: $4.85 billion (2011) Per Share Earnings: $4.05 (2011) Ten-Year Average Annual Growth for Per Share Earnings: 12.2% Per Share Book Value: $16.60 (2011) Market Price: $45 a share (2011) Dividend/Yield 2011: $0.72/1.37% Years of Berkshire Purchase: 1994, 1995, 1998, 2000 Average Per Share Price Berkshire Paid: $8.44 Stock Exchanges: NYSE Ticker Symbol: AXP 7. AMERICAN EXPRESS’S PER SHARE EARNINGS HISTORY YEAR EPS (Earnings Per Share, $) ’11 4.05 ’10 3.35 ’09 1.54 ’08 2.33 ’07 3.29 ’06 2.82 ’05 2.30 ’04 2.74 ’03 2.31 ’02 2.01 ’01 1.28 PER SHARE BOOK VALUE HISTORY YEAR BVPS (Book Value Per Share, $) ’11 16.60 ’10 13.55 ’09 12.09 ’08 10.21 ’07 9.52 ’06 8.77 ’05 8.50 ’04 12.31 ’03 11.93 ’02 10.62 ’01 9.04 8. The Bank of New York Mellon (BNY Mellon): Key Statistics Address: One Wall Street New York, NY 10286 USA Telephone: (212) 495-1784 Website: http://www.bnymellon.com Industry: Banking/Financial Services Key Statistics: Public Company Founded in 1784 Employees: 42,200 Net Earnings: $2.98 billion (2011) Per Share Earnings: $2.40 (2011) Ten-Year Average Annual Growth for Per Share Earnings: 2.86% Per Share Book Value: $28.00 Ten-Year Average Annual Growth for Per Share Book Value: 12.45% Current Market Price: $21 a share Dividend/Yield 2011: $0.52/2.4% Year of Berkshire Purchase: 2010 Average Per Share Price Berkshire Paid: $26 Stock Exchanges: NYSE Ticker Symbol: BK 9. BNY Mellon EPS History YEAR EPS (Earnings Per Share, $) ’11 2.40 ’10 2.14 ’09 (1.07) ’08 1.20 ’07 2.18 ’06 1.93 ’05 2.03 ’04 1.85 ’03 1.52 ’02 1.24 ’01 1.81 BNY Mellon BVPS History YEAR BVPS (Book Value Per Share, $) ’11 28.00 ’10 26.63 ’09 23.97 ’08 22.00 ’07 25.66 ’06 15.34 ’05 12.81 ’04 11.93 ’03 10.87 ’02 9.21 ’01 8.66 10. Coca-Cola Company: Key Statistics Address: One Coca-Cola Plaza Atlanta, Georgia 30313 USA Telephone: (404) 676-2121 Website: http://www.coca-cola.com Industry: Beverage Area Served: Worldwide Key Statistics: Public Company Founded in 1886 Employees: 139,800 Sales: $46.2 billion (2011) Net Earnings: $8.76 billion (2011) Per Share Earnings: $3.85 (2011) Average Annual Growth for Per Share Earnings: 9.18% Per Share Book Value: $14.60 Average Annual Growth for Per Share Book Value: 12.32% Dividend/Yield 2011: $1.88/2.8% Years of Berkshire Purchase: 1988, 1989, 1994 Average Per Share Price Berkshire Paid: $6.50 Stock Exchanges: NYSE Ticker Symbol: KO 11. ConocoPhillips: Key Statistics Address: 600 North Dairy Ashford Houston, TX 77079 USA Telephone: (918) 661-6600 Website: http://www.conocophillips.com Industry: Global Oil and Petrochemical Company Key Statistics: Public Company Founded in 1877 Employees: 33,800 Sales: $25.1 billion (2011) Net Earnings: $9.9 billion (2011) Per Share Earnings: $8.35 (2011) Average Annual Growth for Per Share Earnings: 11.15% Per Share Book Value: $54.20 (2011) Average Annual Growth for Per Share Book Value: 11.19% Dividend/Yield 2011: $2.64/4.17%(2011) Date of Berkshire Purchase: 2006 to 2007 Average Price Berkshire Paid: $69.66 a share Stock Exchanges: NYSE Ticker Symbol: COP 12. ConocoPhillips EPS History YEAR EPS (Earnings Per Share, $) ’11 8.35 ’10 5.92 ’09 3.24 ’08 10.66 ’07 9.14 ’06 9.99 ’05 9.35 ’04 5.79 ’03 3.35 ’02 1.56 ’01 2.90 ConocoPhillips BVPS History YEAR BVPS (Book Value Per Share, $) ’11 54.20 ’10 47.92 ’09 42.03 ’08 37.27 ’07 56.63 ’06 50.21 ’05 36.22 ’04 29.72 ’03 25.17 ’02 21.59 ’01 18.76 13. Costco Wholesale Corporation: Key Statistics Address: 999 Lake Drive Issaquah, WA 98027 USA Telephone: (425) 313-8100 Website: http://www.costco.com Industry: Discount Retail/Food & Wine/Clothing/ Home Furnishings Key Statistics: Public Company Founded in 1983 Employees: 147,000 Sales: $85 billion (2011) Net Earnings: $1.4 billion (2011) Per Share Earnings: $3.30 (2011) Average Annual Growth for Per Share Earnings: 9.85% Per Share Book Value: $27.90 Average Annual Growth for Per Share Book Value: 9.95% Dividend/Yield 2011: $0.96/1.1% Year of Berkshire Purchase: 2002 Average Per Share Price Berkshire Paid: $34 Stock Exchanges: NDQ Ticker Symbol: COST 14. Costco EPS History YEAR EPS (Earnings Per Share, $) ’11 3.30 ’10 2.93 ’09 2.57 ’08 2.89 ’07 2.63 ’06 2.31 ’05 2.04 ’04 1.86 ’03 1.53 ’02 1.48 ’01 1.29 Costco EVPS History YEAR BVPS (Book Value Per Share, $) ’11 27.90 ’10 24.98 ’09 22.98 ’08 21.25 ’07 19.73 ’06 19.78 ’05 18.80 ’04 16.48 ’03 14.33 ’02 12.51 ’01 10.81 15. GlaxoSmithKline: Key Statistics Address: UK Address Glaxo Wellcome House Berkeley Avenue Greenford, Middlesex, England U.S. Office 1 Franklin Plaza PO Box 7929 Philadelphia, PA 19101 USA U.S.
Load more

Recommended publications
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • Staying on Schedule: How to Take Each HIV Medicine
    11 1 11 12 1 11 1 11 12 1 10 2 10 2 10 2 10 2 9 33 9 33 9 33 9 33 8 4 8 4 8 4 8 4 7 6 5 7 6 5 7 6 5 7 6 5 Staying on Schedule How to take each HIV medicine HIV medicines are a key part of your HIV treatment. They can reduce the amount of HIV in your blood to very low levels and help restore your immune system health and your overall health. When you start taking HIV medicines, it is a big commitment. You have to take HIV medicines on time, exactly as they are prescribed, for them to work properly. What this booklet does: • Shows a picture of each HIV medicine. • Lists the amount of the drug in each dose (the amount you take may vary). • Tells you when to take the medicine and whether or not to eat food with it. • Gives general tips for taking each HIV medicine. An HIV medicine schedule is different for everyone. Your doctor or health care provider will work closely with you to decide which medicines to take and how much to1 take. Ask questions before you start taking a medicine When you pick up a new prescription or a refill of an HIV medicine at the drugstore, read the directions carefully. If you don’t understand anything about taking the medicine, ask the pharmacist to explain. Make sure the medicines look the same as the ones you are taking. Check to see if the instructions for taking them are the same instructions given by your doctor or health care provider.
    [Show full text]
  • NEW Products
    NEW Products NEW Products - January 2021 NEW Generics PIP CODE PRODUCT PACK 1236082 Dexamethasone Tablets 500mcg 28 7747462 Diltiazem Tablets 60mg 84 5018957 Mebeverine 50mg/5ml Oral Suspension 300ml NEW UK Feeds PIP CODE PRODUCT PACK 3655545 Fresubin 2kcal Fibre Apricot/Peach 4x200m 3 NEW Products 3442803 Fresubin 2kcal Fibre Cappucino 4x200m 3438264 Fresubin 2kcal Fibre Chocolate 4x200m 3442795 Fresubin 2kcal Fibre Lemon 4x200m 5 Generics 3655537 Fresubin 2kcal Fibre Neutral 4x200m www.de-group.co.uk 3442944 Fresubin 2kcal Fibre Vanilla Pack 4x200m 4022950 Fresubin 2kcal Mini Apricot/Peach 4x125m 44 Parallel Imports 4022976 Fresubin 2kcal Mini Fibre Chocolate 4x125m 4022984 Fresubin 2kcal Mini Fibre Vanilla 4x125m 4022968 Fresubin 2kcal Mini FOTF 4x125m 3 60 UK Ethicals 4022943 Fresubin 2kcal Mini Vanilla 4x125m 3771334 Polycal Liquid Bottle Neutral 200ml 3771326 Polycal Liquid Bottle Orange 200ml 70 UK Feeds NEW UK Dressings PIP CODE PRODUCT PACK 74 Parallel Import Feeds 3272887 Airzone Peak Flow Meter 15 3793965 Biatain Adhesive 7.5x7.5 10 3798469 Clinifilm Wipes 30 76 Dressings 3902756 Clinimed LBF Foam Applicator 2ml 5 2896439 Clinimed LBF NonSting Bar Film Wipes 30 90 3694924 Cutimed Protect Cream 90g OTC 3694916 Cutimed Protect Cream 28g 3694890 Cutimed Protect Foam 1ml 5 3694908 Cutimed Protect Foam 3ml 5 134 Dispensing 3694882 Cutimed Protect Spray 28ml 3722238 Cutimed Sorbion Sachet Extra 20x10 5 3883402 Cutimed Sorbion Sachet XL 45cmx25cm 5 136 Vets 3942018 Devon Foot And Heel Protector 2 227074 Kaltostat Rope Cavity Wound
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • Preferred Drug List
    Comprehensive PREFERRED DRUG LIST MHS Indiana Effective 04/01/2017 PAGE 1 LAST UPDATED 04/2017 Pharmacy Program MHS Health Plan (MHS) is committed to providing appropriate, high-quality, and cost- effective drug therapy to all MHS members. MHS works with providers and pharmacists to ensure that medications used to treat a variety of conditions and diseases are covered. MHS covers prescription medications and certain over-the-counter (OTC) medications when ordered by an Indiana Medicaid enrolled MHS practitioner. The pharmacy program does not cover all medications. Some medications require prior authorization (PA) or have limitations on age, dosage, and maximum quantities. For the most current information about the MHS Pharmacy Program you may call Member Services at (877) 647-4848 (TTY/TTD (800) 743-3333) or visit the MHS website www.mhsindiana.com. Preferred Drug List The MHS Preferred Drug List (PDL) is the list of covered drugs. The PDL applies to drugs that members can receive at retail pharmacies. The MHS PDL is continually evaluated by the MHS Pharmacy and Therapeutics (P&T) Committee to promote the appropriate and cost-effective use of medications. The Committee is composed of the MHS Medical Director, MHS Pharmacy Director, and several Indiana physicians, pharmacists, and specialists. Pharmacy Benefit Manager Envolve Pharmacy Solutions (EPS) is our Pharmacy Benefit Manager. MHS works with EPS to process all pharmacy claims for prescribed drugs. Some drugs on the MHS PDL require PA, and EPS is responsible for administering this process. Specialty Drugs Certain medications are only covered when supplied by MHS’ specialty pharmacy provider. AcariaHealth is our specialty pharmacy provider.
    [Show full text]
  • Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
    GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
    [Show full text]
  • Preferred Drug List (PDL)
    Preferred Drug List (PDL) New Jersey – MLTSS Effective Date: 7/15/2021 © 2021 United HealthCare Services, Inc. All Rights Reserved. UnitedHealthcare Community Plan does not treat members differently because of sex, age, race, color, disability or national origin. If you think you were treated unfairly because of your sex, age, race, color, disability or national origin, you can send a complaint to: Civil Rights Coordinator UnitedHealthcare Civil Rights Grievance P.O. Box 30608 Salt Lake City, UTAH 84130 [email protected] You must send the complaint within 60 days of when you found out about it. A decision will be sent to you within 30 days. If you disagree with the decision, you have 15 days to ask us to look at it again. If you need help with your complaint, please call the toll-free member phone number listed on your health plan member ID card, TTY 711, 24 hours a day, 7 days a week. You can also file a complaint with the U.S. Dept. of Health and Human Services. Online: https://ocrportal.hhs.gov/ocr/portal/lobby.jsf Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html Phone: Toll-free 1-800-368-1019, 1-800-537-7697 (TDD) Mail: U.S. Dept. of Health and Human Services 200 Independence Avenue SW Room 509F, HHH Building Washington, D.C. 20201 If you need help with your complaint, please call the toll-free member phone number listed on your member ID card. We provide free services to help you communicate with us, such as letters in other languages or large print.
    [Show full text]
  • GCE a Level 1083/01 BUSINESS STUDIES –
    GCE A level 1083/01 S15-1083-01 BUSINESS STUDIES – BS3 A.M. WEDNESDAY, 10 June 2015 2 hours 1083 010001 ADDITIONAL MATERIALS In addition to this examination paper, you will need: • a calculator; • a 12 page answer book. INSTRUCTIONS TO CANDIDATES Use black ink or black ball-point pen. Answer all the questions. Write your answers in the separate answer book provided. INFORMATION FOR CANDIDATES The number of marks is given in brackets at the end of each question. You are reminded that assessment will take into account the quality of written communication used in answers that involve extended writing in questions 4 and 5. You are reminded that questions 4 and 5 are synoptic and so will test understanding of the connections between different elements of the subject. © WJEC CBAC Ltd. AM*(S15-1083-01) 2 Study the information provided about GlaxoSmithKline plc and answer the questions that follow. BACKGROUND GlaxoSmithKline plc (GSK) is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. It has three primary areas of business: pharmaceuticals, vaccines and consumer healthcare. Its consumer products include 5 Ribena, Macleans toothpaste, Panadol headache pills, Lucozade and Horlicks. The company can trace its history back to 1715 when Sylvanus Bevan established his pharmacy in Plough Court in London. In 1880, his descendants founded Burroughs Wellcome and Company which, eventually in 1995, merged with the Australian company Glaxo to form Glaxo Wellcome. The American branch of the business can trace its history back to 1830 when John K Smith 10 opened his first drugstore.
    [Show full text]
  • Pharmaceutical Giant Consolidates Worldwide Facilities Management Services
    CASE STUDY From 300 to 3: Pharmaceutical Giant Consolidates Worldwide Facilities Management Services Client: GlaxoSmithKline The Opportunity Matter: Outsourcing contract strategy, UK-headquartered GlaxoSmithKline (GSK) is a FTSE structuring and negotiation 100-listed research-based pharmaceutical company that employs 99,000 people in more than 100 countries. GSK Area of Law: Outsourcing has a seven percent share of the world medicine/medical Result: Significantly increased profits and efficiency product market and, through its consumer health division, for GSK by replacing more than 300 sells products under household-name brands like alli, worldwide service providers using unique Ribena, Horlicks, Lucozade, Aquafresh, Sensodyne contracts with a select number of global and Panadol. providers using standardised agreements. GSK has grown both organically and through acquisition, contracting service suppliers one at a time as the need arose. By the time it enlisted Pillsbury’s help, GSK’s facilities management services spanned 300 suppliers across multiple sites and product lines, each with its own locally developed service levels and pricing models. GSK sought to simplify its operating model with a stand- ardised, scalable solution with consistent, measurable service levels delivered through a few global providers. The Challenge The scale of the project added significant complexity to the lifecycle aspects of the arrangement—from strategy, due diligence, contracting and transition to operational management and global rollout. GSK selected
    [Show full text]
  • Laws of Trinidad and Tobago Ministry of Legal Affairs
    LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt FOOD AND DRUGS ACT CHAPTER 30:01 Act 8 of 1960 Amended by 39 of 1968 156/1972 *31 of 1980 16 of 1986 12 of 1987 6 of 1993 16 of 1998 6 of 2005 *See Note on Validation at page 2 Current Authorised Pages Pages Authorised (inclusive) by L.R.O. 1–2 .. 3–20 .. 21–245 .. UNOFFICIAL VERSION L.R.O. UPDATED TO DECEMBER 31ST 2014 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt 2 Chap. 30:01 Food and Drugs Index of Subsidiary Legislation Page Food and Drugs Regulations (GN 130/1964) … … … … 25 Official Method Notification (GN 54/1972) … … … … 124 *Approval of New Drugs Notification … … … … … 129 †Withdrawal of Approval of New Drugs Notification (GN 51/1969) … … 200 Fish and Fishery Products Regulations (LN 220/1998)…………201 †This Notification (i.e. 51/1969) has been amended by LNs 99 and 114/1984 which have been omitted. *Note on Approval of New Drugs Notification The list of new drugs set out in the Schedule to this Notification has been consolidated as at 31st December 1977. This list is so voluminous and changes to it so frequent that, especially in view of its very limited use by the general public, it is not practicable to update it annually. The references to the amendments to this list since 31st December 1977 are contained in the Current Consolidated Index of Acts and Subsidiary Legislation. †Note on Withdrawal of Approval of New Drugs Notification For references to the Withdrawal of Approval of New Drugs Notifications subsequent to the year 1969 — See the current Consolidated Index of Acts and Subsidiary Legislation.
    [Show full text]
  • Cambridgeshire Joint Prescribing Group 2004
    Date Printed 13/12/201722/11/201721/11/201728/09/2017 Current Commissioning Indication Last date Relevant Approved name Classification and Responsibility Rationale for Next Review Covered by this classified by NICE (Brand Name) Priority Funding Decision Due Classification CPJPG Guidance Position NHSE CCG CAMBRIDGESHIRE & PETERBOROUGH CCG FORMULARY Classification of Prescribing Responsibility Skip to Alphabetical Index Foreword This document is an appendix to the Cambridgeshire and Peterborough CCG Formulary Medicines considered by the CPJPG are included in this document. In general, only medicines classified as ‘NOT RECOMMENDED’ and ‘HOSPITAL ONLY’ are retained in this document long-term whilst all others are removed after 6 months as they are included in the CCG Formulary. Definitions of the recommendations made by the Cambridgeshire and Peterborough Joint Prescribing Group (CPJPG) can be found in the explanatory notes Any medication/drug licensed or becoming available after the revision date (below) for this document and not considered by CPJPG should be regarded as ‘Not Recommended’ or ‘Hospital only’. Omission of a drug from this table cannot be taken to indicate that it is recommended for prescribing in either primary or secondary care. (i.e. any medicine not listed in either the classification table or the formulary are classified as “Not recommended” ) Please contact the Medicines Management Team for further advice. Cambridgeshire and Peterborough CCG have undertaken a prioritisation process and agreed that some therapies will not be a priority for funding and will therefore not be funded other than in exceptional circumstances. This appendix to the formulary is a continually evolving document and will be updated after each CPJPG meeting (every 2 months).
    [Show full text]
  • Food and Drugs Act 2005
    LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt FOOD AND DRUGS ACT CHAPTER 30:01 Act 8 of 1960 Amended by 39 of 1968 156/1972 *31 of 1980 16 of 1986 12 of 1987 6 of 1993 16 of 1998 6 of 2005 *See Note on Validation at page 2 Current Authorised Pages Pages Authorised (inclusive) by L.R.O. 1–2 .. 1/2009 3–20 .. 1/2006 21–245 .. 1/2009 L.R.O. 1/2009 UPDATED TO DECEMBER 31ST 2009 LAWS OF TRINIDAD AND TOBAGO MINISTRY OF LEGAL AFFAIRS www.legalaffairs.gov.tt 2 Chap. 30:01 Food and Drugs Index of Subsidiary Legislation Page Food and Drugs Regulations (GN 130/1964) … … … … 25 Official Method Notification (GN 54/1972) … … … … 124 *Approval of New Drugs Notification … … … … … 129 †Withdrawal of Approval of New Drugs Notification (GN 51/1969) … … 200 Fish and Fishery Products Regulations (LN 220/1998)…………201 †This Notification (i.e. 51/1969) has been amended by LNs 99 and 114/1984 which have been omitted. *Note on Approval of New Drugs Notification The list of new drugs set out in the Schedule to this Notification has been consolidated as at 31st December 1977. This list is so voluminous and changes to it so frequent that, especially in view of its very limited use by the general public, it is not practicable to update it annually. The references to the amendments to this list since 31st December 1977 are contained in the Current Consolidated Index of Acts and Subsidiary Legislation. †Note on Withdrawal of Approval of New Drugs Notification For references to the Withdrawal of Approval of New Drugs Notifications subsequent to the year 1969 — See the current Consolidated Index of Acts and Subsidiary Legislation.
    [Show full text]